Standout Papers

Cancer immunotherapy: moving beyond current vaccines... 1987 2026 2000 2013 2.2k
  1. Cancer immunotherapy: moving beyond current vaccines (2004)
    Steven A. Rosenberg, James C. Yang et al. Nature Medicine
  2. A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone (1987)
    Steven A. Rosenberg, Michael T. Lotze et al. New England Journal of Medicine
  3. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes (2002)
    Mark E. Dudley, John R. Wunderlich et al. Science
  4. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial (2014)
    Daniel W Lee, James N. Kochenderfer et al. The Lancet
  5. A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer (2003)
    James Chih‐Hsin Yang, Leah Haworth et al. New England Journal of Medicine
  6. Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer (1985)
    Steven A. Rosenberg, Michael T. Lotze et al. New England Journal of Medicine
  7. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes (2006)
    Richard A. Morgan, Mark E. Dudley et al. Science
  8. Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 (2010)
    Richard A. Morgan, James C. Yang et al. Molecular Therapy
  9. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. (1982)
    Elizabeth A. Grimm, A Mazumder et al. The Journal of Experimental Medicine
  10. Adoptive cell transfer as personalized immunotherapy for human cancer (2015)
    Steven A. Rosenberg, Nicholas P. Restifo Science
  11. Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma (1988)
    Steven A. Rosenberg, Beverly S. Packard et al. New England Journal of Medicine
  12. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy (2011)
    Steven A. Rosenberg, James Chih‐Hsin Yang et al. Clinical Cancer Research
  13. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 (1999)
    Michael B. Atkins, Michael T. Lotze et al. Journal of Clinical Oncology
  14. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma (1998)
    Steven A. Rosenberg, James Chih‐Hsin Yang et al. Nature Medicine
  15. A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes (1986)
    Steven A. Rosenberg, Paul J. Spiess et al. Science
  16. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired (2009)
    Mojgan Ahmadzadeh, Laura A. Johnson et al. Blood
  17. Adoptive immunotherapy for cancer: harnessing the T cell response (2012)
    Nicholas P. Restifo, Mark E. Dudley et al. Nature reviews. Immunology
  18. Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer (2014)
    Eric Tran, Simon Turcotte et al. Science
  19. Adoptive cell transfer: a clinical path to effective cancer immunotherapy (2008)
    Steven A. Rosenberg, Nicholas P. Restifo et al. Nature reviews. Cancer
  20. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma (2003)
    Giao Q. Phan, James Chih‐Hsin Yang et al. Proceedings of the National Academy of Sciences
  21. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells (2011)
    James N. Kochenderfer, Mark E. Dudley et al. Blood
  22. Progress in human tumour immunology and immunotherapy (2001)
    Steven A. Rosenberg Nature
  23. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 (2010)
    James N. Kochenderfer, Wyndham H. Wilson et al. Blood
  24. Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens (2008)
    Mark E. Dudley, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  25. The Treatment of Soft-tissue Sarcomas of the Extremities (1982)
    Steven A. Rosenberg, Joel E. Tepper et al. Annals of Surgery
  26. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (2006)
    Michael H. Kershaw, Jennifer A. Westwood et al. Clinical Cancer Research
  27. T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 Years (1995)
    R. Michael Blaese, Kenneth W. Culver et al. Science
  28. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma (2010)
    Richard E. Royal, Catherine Lévy et al. Journal of Immunotherapy
  29. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer (2016)
    Eric Tran, Paul F. Robbins et al. New England Journal of Medicine
  30. IL-2: The First Effective Immunotherapy for Human Cancer (2014)
    Steven A. Rosenberg The Journal of Immunology
  31. Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction (1990)
    Steven A. Rosenberg, Paul Aebersold et al. New England Journal of Medicine
  32. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. (1994)
    Yutaka Kawakami, S Eliyahu et al. Proceedings of the National Academy of Sciences
  33. Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2 (1994)
    Steven A. Rosenberg JAMA
  34. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells (2013)
    Paul F. Robbins, Yong‐Chen Lu et al. Nature Medicine
  35. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells (2005)
    Luca Gattinoni, Steven E. Finkelstein et al. The Journal of Experimental Medicine
  36. Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients (1989)
    Steven A. Rosenberg, Michael T. Lotze et al. Annals of Surgery
  37. T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis (2010)
    Maria R. Parkhurst, James C. Yang et al. Molecular Therapy
  38. Treatment of Patients With Metastatic Melanoma With Autologous Tumor-Infiltrating Lymphocytes and Interleukin 2 (1994)
    Steven A. Rosenberg, John R. Yannelli et al. JNCI Journal of the National Cancer Institute
  39. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4 (2005)
    Peter Attia, Giao Q. Phan et al. Journal of Clinical Oncology
  40. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors (2014)
    Alena Gros, Paul F. Robbins et al. Journal of Clinical Investigation
  41. Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells (2003)
    Willem W. Overwijk, Marc R. Theoret et al. The Journal of Experimental Medicine
  42. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. (1994)
    Yutaka Kawakami, S Eliyahu et al. Proceedings of the National Academy of Sciences
  43. Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells (2005)
    Christopher A. Klebanoff, Luca Gattinoni et al. Proceedings of the National Academy of Sciences
  44. Adoptive immunotherapy for cancer: building on success (2006)
    Luca Gattinoni, Daniel J. Powell et al. Nature reviews. Immunology
  45. Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4 (2006)
    Joseph Blansfield, Khoi Q. Tran et al. Journal of Clinical Oncology
  46. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients (2016)
    Alena Gros, Maria R. Parkhurst et al. Nature Medicine
  47. CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005)
    Paul A. Antony, Ciriaco A. Piccirillo et al. The Journal of Immunology
  48. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response (2014)
    Paul F. Robbins, Sadik H. Kassim et al. Clinical Cancer Research
  49. Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer (2003)
    James Chih‐Hsin Yang, Richard M. Sherry et al. Journal of Clinical Oncology
  50. Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2 (1984)
    James J. Mulé, Suyu Shu et al. Science
  51. Immunogenicity of somatic mutations in human gastrointestinal cancers (2015)
    Eric Tran, Mojgan Ahmadzadeh et al. Science
  52. Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma (2002)
    John Toso, Vee J. Gill et al. Journal of Clinical Oncology
  53. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer (2018)
    Nikolaos Zacharakis, Harshini Chinnasamy et al. Nature Medicine
  54. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis (2007)
    James Chih‐Hsin Yang, Marybeth S. Hughes et al. Journal of Immunotherapy
  55. Adoptive-cell-transfer therapy for the treatment of patients with cancer (2003)
    Mark E. Dudley, Steven A. Rosenberg Nature reviews. Cancer
  56. Generation of Tumor-Infiltrating Lymphocyte Cultures for Use in Adoptive Transfer Therapy for Melanoma Patients (2003)
    Mark E. Dudley, John R. Wunderlich et al. Journal of Immunotherapy
  57. Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli (1984)
    Steven A. Rosenberg, Elizabeth A. Grimm et al. Science
  58. Identification of human cancers deficient in antigen processing. (1993)
    Nicholas P. Restifo, Fernando Esquivel‐Guadarrama et al. The Journal of Experimental Medicine
  59. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade (2007)
    Jacob A. Klapper, Franz O. Smith et al. Clinical Cancer Research
  60. Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer (2010)
    Rajeev Shrimali, Zhiya Yu et al. Cancer Research
  61. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients (2005)
    Mojgan Ahmadzadeh, Steven A. Rosenberg Blood
  62. Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus–Targeted Tumor-Infiltrating T Cells (2015)
    Sanja Stevanović, Lindsey M. Draper et al. Journal of Clinical Oncology
  63. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. (1985)
    Michael T. Lotze, Yvedt L. Matory et al. The Journal of Immunology
  64. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. (1986)
    Maury Rosenstein, Stephen E. Ettinghausen et al. The Journal of Immunology
  65. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. (1981)
    Michael T. Lotze, Elizabeth A. Grimm et al. PubMed
  66. TRANSPLANTATION IN MINIATURE SWINE (1976)
    David H. Sachs, George S. Leight et al. Transplantation
  67. The grading of soft tissue sarcomas results of a clinicohistopathologic correlation in a series of 163 cases (1984)
    José Costa, Robert Wesley et al. Cancer
  68. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer (2022)
    Rom S. Leidner, David E. Sprott et al. New England Journal of Medicine
  69. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer (2020)
    Gal Cafri, Jared J. Gartner et al. Journal of Clinical Investigation
  70. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma (2019)
    Stephanie L. Goff, Richard A. Morgan et al. Journal of Immunotherapy

Immediate Impact

97 by Nobel laureates 63 from Science/Nature 356 standout
Sub-graph 1 of 14

Citing Papers

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
12 intermediate papers

Works of Steven A. Rosenberg being referenced

Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells
2005 Standout
and 46 more

Author Peers

Author Last Decade Papers Cites
Steven A. Rosenberg 87467 88521 37374 939 138.6k
Alberto Mantovani 90088 44401 41830 1.1k 154.3k
Drew M. Pardoll 46168 44257 23146 398 81.6k
Lloyd J. Old 46929 33262 32823 714 84.6k
Carl H. June 40036 50894 23836 649 83.3k
Ira Pastan 20106 29761 45198 1.2k 89.2k
Laurence Zitvogel 41768 30721 31005 488 77.2k
Mark J. Smyth 52200 36937 19880 592 80.1k
James P. Allison 49382 38454 12845 480 70.9k
Hans Clevers 14772 52291 96581 721 156.0k
Zena Werb 18208 34757 45042 411 108.4k

All Works

Loading papers...

Rankless by CCL
2026